Latest From 4Tech Inc.
Early results of the TRILUMINATE trial presented at the EuroPCR conference will support a CE mark for a version of MitraClip adapted to reduce tricuspid valve regurgitation.
The TRILUMINATE trial will evaluate safety and effectiveness of its Tricuspid Valve Repair System for treating symptomatic moderate-to-severe tricuspid regurgitation. The device is similar to Abbott's successful MitraClip catheter-based device for treating mitral regurgitation.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Medtech veteran Bill Hawkins is the new board chair of 4Tech, a startup developing transcatheter tricuspid valve repair devices.
- Implantable Devices
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- 4Tech Inc.
- Senior Management
Tom Fleming, Pres. & CEO
Keith Dawkins, MD, CMO
- Contact Info
Ballybrit Business Park
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.